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Introduction
Th  e development in 1984 of consensus criteria [1] for 
diagnosis of Alzheimer’s disease (AD) capped a period of 
evolving knowledge that AD could be diﬀ  erentiated not 
only from normal aging but also from other causes of 
neurodegenerative dementias. On average, clinical diag-
nosis using these consensus criteria is approximately 81% 
sensitive and 70% speciﬁ  c compared to the gold standard, 
pathology at autopsy [2], a performance that equals or 
exceeds the performance of proposed diagnostic criteria 
for many other neurodegenerative diseases [2,3].
Nevertheless, there remains both room and a need for 
improvement in diagnostic accuracy. Up to 20% of 
subjects clinically diagnosed with AD do not have AD 
pathology at autopsy [4-6], a percentage that is essentially 
unchanged from the estimate in the 1984 consensus 
publication [1]. In addition, under-diagnosis in the 
commu  nity setting is signiﬁ  cant. Approximately 10% of 
community-dwelling elderly have undiagnosed dementia 
[7,8] and community physicians may fail to diagnose up 
to 33% of individuals with mild dementia [8].
Perhaps the biggest limitation in current practice is a 
reliance on the presentation and progression of 
symptoms to identify an AD phenotype. Th  is  inherently 
leads to delays in diagnosis as physicians must wait for 
symptoms to appear and must track progressive decline 
over time. However, the past 25 years have seen dramatic 
improvements in technology and understanding of bio-
markers that oﬀ  er potential to improve this diagnostic 
algorithm. As a result, new draft criteria [9,10] have 
proposed that diagnosis can be enhanced by use of 
biomarkers to increase certainty, and, in early stages, to 
identify prodromal AD. Th   is approach has the potential 
to allow earlier and more speciﬁ   c diagnosis and will 
possibly identify patients with AD before the point where 
irreversible damage precludes eﬀ  ective treatment [11].
A number of diﬀ  erent biomarkers, including atrophy 
on magnetic resonance imaging (MRI), regional metabo-
lism as assessed by 18F-ﬂ  uorodeoxyglucose  positron 
emis  sion tomography (PET), and cerebrospinal ﬂ  uid 
(CSF) concentrations of tau and β-amyloid (Aβ) are 
poten  tially useful [11,12], but molecular imaging with 
amyloid targeted PET ligands is a particularly attractive 
approach. Rate of atrophy on volumetric MRI and pattern 
of metabolic deﬁ  cits on 18F-ﬂ  uorodeoxyglucose PET can 
provide useful information on stage of deterioration and 
functional status, but may lack speciﬁ  city, since multiple 
types of neurologic disorders can cause the same type of 
changes [13-17]. CSF markers provide information (albeit 
indirect) more relevant to the underlying molecular 
pathology, including both Aβ and tau, but require a 
relatively invasive procedure (lumbar puncture) and may 
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© 2011 BioMed Central Ltdnot be entirely speciﬁ   c for AD [18]. In contrast, Aβ 
imaging potentially provides a direct, relatively non-
invasive estimate of brain Aβ burden, which together 
with tau and a progressive pattern of neuronal loss is a 
deﬁ  ning pathology and an import link in the pathogenesis 
of AD [19,20].
Th  e ﬁ  rst, and to date most widely studied, ligand for 
PET imaging of Aβ aggregates (subsequently referred to 
as amyloid PET or amyloid imaging) is the 11C-labeled 
agent known as Pittsburgh compound B (PIB) [21-23]. 
Although 11C-PIB has been a highly valuable tool in the 
research setting, the short (20-minute) half-life of the 11C 
label limits the utility of 11C-PIB in routine clinical 
application. Th  us, there has been a push to develop a 
longer lived 18F-labeled amyloid PET agent. Th  ree com-
pounds are currently in the late stages of development. 
One of these, ﬂ  orbetapir F 18 [24-26] has now completed 
phase III trials [27], while ﬂ  orbetaben [28] and ﬂ  utemeta-
mol [29,30] are currently enrolling to phase III trials.
Th  e utility of PET amyloid imaging as an aid in early 
diagnosis rests on three major assumptions: ﬁ  rst, that 
PET imaging accurately reﬂ  ects Aβ burden in the brain; 
second, that PET imaging can detect brain Aβ at an early 
stage of disease, that is, prior to the onset of dementia; 
and ﬁ  nally, that the presence of β-amyloid, as detected by 
PET imaging, has consequences for current and future 
cognitive performance. We will examine the available 
evidence for each of these assumptions in turn.
Relationship between PET amyloid imaging and 
brain Aβ burden by histopathology
In vitro studies have shown that PET imaging ligands 
such as 11C-PIB [21,31], ﬂ  orbetaben [32] and ﬂ  orbetapir 
F 18 [24] bind to Aβ and co-localize with plaques stained 
by thioﬂ  avin and other amyloid labeling agents. However, 
a deﬁ  nitive demonstration of the relationship requires a 
comparison between in vivo imaging and brain pathology, 
for example, at autopsy.
Five single subject/single center PET to pathology 
comparison studies with 11C-PIB have produced mixed 
results. Two studies described patients with clinical diag-
nosis and autopsy conﬁ  rmation of dementia with Lewy 
bodies (DLB) who had amyloid-positive 11C-PIB PET 
scans in life, and borderline Aβ pathology at autopsy. 
Bacskai and colleagues [33] reported a visually positive 
11C-PIB PET scan from a 76 year old with DLB and severe 
cerebral amyloid angiopathy. Regional quantiﬁ  cation of 
the PET image, expressed as distribution volume ratio 
(DVR), revealed low to moderately elevated tracer levels 
(DVR = 1.3 to 1.5), which was consistent with the autopsy 
ﬁ  ndings of low to moderate levels of diﬀ  use plaques and 
infrequent cored plaques (intermediate probability of AD 
by National Institute of Aging - Reagan Institute (NIA-
Reagan) [34] criteria). However, there was no relationship 
across brain regions between regional DVR and regional 
levels of Aβ42 in autopsy tissue as assessed by ELISA. 
Kantarci and colleagues [35] reported a positive 11C-PIB 
PET scan from a 77 year old with DLB. At autopsy 
neuritic plaques were moderately common in some brain 
regions, including mid-frontal gyrus, amygdale and 
superior parietal lobe, but sparse in the areas used for 
pathological diagnosis, resulting in an NIA-Reagan 
classiﬁ   cation of low likelihood AD. In contrast to the 
previous study, there was a strong correlation between 
regional quantiﬁ  cation of the PET image and regional Aβ 
density by immunohistochemistry at autopsy. Two other 
reports studied subjects with a clinical diagnosis of AD. 
Ikonomovic and colleagues [31]  reported an amyloid 
positive  11C-PIB PET scan in a 64 year old with severe 
AD. Strong correlations (0.7 to 0.8) were seen between 
regional  11C-PIB PET tracer uptake (DVR) and various 
postmortem measures of Aβ burden, including immuno-
histochemistry, histopathology and Aβ levels by ELISA. 
Cairns and colleagues [36] reported on a 91 year old with 
clinical diagnosis of early AD with a negative 11C-PIB 
PET scan but reduced CSF Aβ. Th  e autopsy revealed 
numerous diﬀ  use plaques, but sparse cored plaques and 
isolated neuroﬁ   brillary tangles (NFT). Th  e  neuro-
pathologic diagnosis in this subject was borderline: low 
probability of AD by NIA-Reagan criteria, and possible 
AD by CERAD (Consortium to Establish a Registry for 
Alzheimer’s Disease) criteria [37]. Addition ally,  the  11C-
PIB PET scan was taken more than 2 years prior to 
autopsy. Th  us, it is diﬃ   cult to determine whether this 
case should be considered a failure of the 11C-PIB PET 
scan to detect an early stage of AD, or a successful 
rejection of a case that lacked convincing AD pathology. 
Finally, Leinonen and colleagues [38] reported that ﬁ  ve of 
ten subjects who had a tissue removed for a shunt for 
normal pressure hydrocephalis had signiﬁ  cant numbers 
of Aβ aggregates by immunohistochemistry at biopsy. 
Four of these subjects had abnormal 11C-PIB PET scans 
(elevated cortex to cerebellum standard uptake volume 
ratio (SUVR)). Th  e overall correlation between SUVR 
and number of amyloid aggregates across the ten subjects 
was 0.85.
Clark and colleagues [27] recently reported the ﬁ  rst 
prospective multicenter phase III study to evaluate the 
correlation between the level of cortical amyloid burden 
on PET scan and true Aβ burden assessed by postmortem 
histopathology. In this study, 152 subjects with cognitive 
status ranging from cognitively normal to mild cognitive 
impairment (MCI) to AD or other dementing disorders 
agreed to both ﬂ   orbetapir-PET scan and subsequent 
autopsy. As speciﬁ  ed by the protocol, the ﬁ  rst six subjects 
to come to autopsy were considered front runners and 
were used to conﬁ  rm the experimental methods, and the 
next 29 subjects to come to autopsy were considered the 
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ﬂ  orbetapir-PET scans was visually assessed on a 0-to-4 
scale (no-to-high cortical tracer uptake) by three inde-
pen  dent raters, blinded to clinical information, with the 
median rater score as the primary outcome variable, and 
by a semi-automated quantiﬁ  cation of the SUVR in six 
cortical target areas (frontal, temporal and parietal cortex, 
precuneus, anterior and posterior cingulate) relative to the 
cerebellum reference region. Amyloid burden at autopsy 
was assessed by quantitative immunohistochemistry 
(primary outcome variable) and by a modiﬁ  ed CERAD 
scoring (silver stain) in the six cortical target regions. Th  e 
results showed a strong, statistically signiﬁ  cant 
correlation between the level of cortical tracer uptake in 
the PET image, whether assessed by median visual read 
or SUVR, and true Aβ burden, whether assessed post-
mortem by quantitative immunohistochemistry or silver 
stain (ρ = 0.71 to 0.78, P < 0.0001). Similar results were 
obtained in the primary eﬃ   cacy set (n = 29) and in the 
entire autopsy data set (n = 35, including the front 
runners). Th  ere was qualitative agreement between 
ﬂ  orbetapir-PET and postmortem results in 97% of the 
autopsied subjects. Of 19 subjects that met pathologic 
criteria (CERAD and NIA-Reagan) for AD, 18 were rated 
visually positive for amyloid by median read, and all 19 
had SUVR above a predeﬁ  ned cutpoint. Conversely, all 
16 subjects that did not meet pathologic criteria (amyloid 
free) at autopsy were amyloid free by both visual and 
quantitative analysis of the PET scan.
Although the data with 11C-PIB are somewhat limited, 
the results with ﬂ   orbetapir F 18 provide a strong 
preliminary indication that PET amyloid imaging can 
provide an accurate reﬂ  ection of underlying Aβ burden. 
However, further studies are required to understand how 
early in the disease course the amyloid pathology can be 
detected. In both the 11C-PIB [36,38] and ﬂ  orbetapir F 18 
[27] studies there were some subjects with measurable 
but low levels of amyloid pathology at autopsy that were 
not associated with amyloid-positive PET scans. In most 
cases, the level of pathology in these patients at autopsy 
was below the threshold for neuropathological diagnosis 
of AD (that is, rated low likelihood or no AD). Th  us,  the 
threshold for detection of amyloid on the PET scan 
appears close to the levels of neuropathology typical for a 
diagnosis of AD. It is presently unclear whether levels of 
Aβ burden at autopsy that are insuﬃ   cient to be thought 
of as AD actually represent an early stage of disease 
[35,36], or whether they represent variants of amyloid 
deposition, including normal aging [39]. Longitudinal 
studies, with periodic repeat scans and cognitive testing, 
would be useful to determine how much or for how long 
a negative scan in a cognitively normal individual reduces 
risk of future amyloid accumulation and cognitive 
impairment. Such studies are now starting as part of the 
second phase Alzheimer’s Disease Neuroimaging 
Initiative (ADNI; for example, ADNI-2) protocol [40].
On the other hand, across both the 11C-PIB and the 
ﬂ   orbetapir F 18 image/autopsy studies there were no 
cases in which a positive amyloid PET scan was obtained 
in a subject found to be cognitively normal and amyloid 
free at autopsy. Th   ese results suggest that there is a high 
probability of underlying brain Aβ pathology in subjects 
with positive amyloid PET scans. Th  is kind of high 
speciﬁ  city and positive predictive value, compared to the 
autopsy gold standard, is a prerequisite for a biomarker 
to be used as an aid to early diagnosis of dementia.
Early detection of amyloid by PET imaging in MCI 
and cognitively normal subjects
Current theories of AD pathophysiology hold that Aβ 
deposition may be a precipitating event that begins years 
in advance of the onset of dementia [41-43]. Evidence in 
support of the hypothesis includes the ﬁ  nding that 15% 
or more of cognitively normal subjects coming to autopsy 
may have plaque burden suﬃ   cient to support a diagnosis 
of AD [44-46] and 33 to 62% of subjects with MCI have 
signiﬁ  cant accumulation of Aβ plaques [47,48]. Corres-
pond  ing changes in biomarkers have also been reported 
in non-demented individuals. Notably, studies of CSF 
biomarkers have consistently shown decreases in CSF Aβ 
in 30 to 40% of cognitively normal subjects [49,50]. 
Changes in CSF tau, MRI volume and cerebral metabo-
lism may occur slightly later than changes in CSF Aβ 
[41,49,51].
Amyloid PET imaging studies have yielded results 
similar to those from autopsy and CSF studies. Studies 
using 11C-PIB have reported amyloid-positive scans in 14 
to 47% of cognitively normal elderly volunteers [40,43, 
52-55], and 55 to 72% of subjects with MCI [51,54-57]. 
Where data from both 11C-PIB PET scans and CSF Aβ 
have been available, strong correlations between these 
measures have generally been reported [49,57]. Results 
with  18F-labeled imaging agents are similar to those for 
11C-PIB. Th  e proportion of Aβ-positive scans in cogni-
tively normal subjects has ranged from 7% and 12% with 
ﬂ  utametamol [29,30], to 13% with ﬂ  orbetapir [26], and 
20% with ﬂ  orbetaben [28]. In MCI subjects the propor-
tion of positive scans was about 50% for ﬂ  utametamol 
[30] and ﬂ  orbetaben [58] and about 38% in the studies 
with ﬂ  orbetapir [59].
Th  e  diﬀ  erences across PET studies, which are similar to 
the diﬀ  erences in the pathological studies of cognitively 
normal controls and MCI, could easily be related to 
diﬀ  erences in subject age and inclusion criteria rather 
than diﬀ   erences in sensitivity of the diﬀ  erent  tracers. 
Consistent with ﬁ  ndings in the autopsy literature [45,60], 
the proportion of cognitively healthy control subjects 
that are Aβ-positive by PET scan increases with age 
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subjects varied by more than 10 years across the studies 
above [29,55]. Additionally, the ﬂ  orbetapir trial [58] was 
designed to evaluate early stage MCI patients, diagnosed 
within the past year. Th   ese subjects may be more diﬃ   cult 
to diagnose and thus more heterogeneous, leading to 
inclusion of a greater number of subjects with non-
amyloid/AD-related impairments.
Jagust and colleagues [40], reporting on 11C-PIB sub-
jects from the ADNI study, further evaluated quantitative 
values (cortical to cerebellar SUVR) for the Aβ-positive 
and Aβ-negative subjects by diagnostic presentation 
group (cognitively healthy, MCI and AD). Interestingly, 
there was no apparent diﬀ  erence in SUVR between Aβ-
positive MCI and Aβ-positive AD, but SUVR in Aβ-
positive MCI and AD both appeared greater than SUVR 
in Aβ-positive healthy controls. Th   ese results are consis-
tent with histopathology ﬁ  ndings [47], indicating that the 
relative proportion of patients with high versus moderate 
levels of Aβ pathology at autopsy (deﬁ  nite  versus 
probable AD by CERAD criteria) does not increase from 
MCI to AD patients, and suggests that Aβ accumulation 
reaches asymptote at early stages of disease.
Together with the image-autopsy results described 
above [27], these results suggest that PET imaging can 
detect the presence of Aβ aggregates suﬃ   cient to support 
a pathological diagnosis of AD in upwards of 15% of 
cognitively healthy elderly subjects (prevalence increas-
ing with age) as well as in 40 to 70% of subjects with MCI. 
Th   us, the results are consistent with the hypothesis [41] 
that PET amyloid imaging can detect Aβ accumulation 
well in advance of the onset of dementia. Th   e next section 
will consider the available literature regarding conse-
quences of a positive amyloid scan for present and future 
cognitive performance in cognitively healthy and MCI 
subjects.
Relationship between amyloid PET imaging and 
cognitive performance/progression
Th   e most obvious prediction from the model of Jack and 
colleagues [41] is that compared to subjects who have a 
negative amyloid PET scan, cognitively healthy control 
and MCI subjects who have positive amyloid PET scans 
will, as a group, show greater deterioration in cognitive 
performance, and will be more likely to progress to an 
advanced stage of disease (for example, from MCI to 
AD). A signiﬁ  cant number of studies have looked at the 
relationship between PET amyloid binding and concur-
rent cognitive performance. Multiple studies have 
reported no correlation between amyloid binding and 
degree of cognitive deﬁ  cits in AD patients [55,61,62]. Th  is 
is consistent with the hypothesis that amyloid is an early 
initiating event in a pathological cascade, that Aβ accu-
mulation approaches asymptote by the time that 
symptoms appear, and that other pathological processes 
(tau phosphorylation, inﬂ  ammation, synaptic degenera-
tion) are more closely linked to expression of cognitive 
impairment in AD patients [41].
Results are more mixed for MCI subjects. Pike and 
colleagues [55] found a good correlation (r = 0.61) between 
11C-PIB SUVR and a working memory compo  site score. 
Others have found no consistent diﬀ  erences in cognition 
as a function of PET amyloid imaging [43,54]. However, it 
is likely that correlational studies in MCI subjects are 
particularly sensitive to the diagnostic algorithms used to 
select and deﬁ   ne MCI subjects. Overlap between the 
diagnostic algorithm and cognitive outcome variables 
can reduce the chances of ﬁ  nding a relationship between 
an independent variable and cognitive performance; for 
example, if all subjects must have objectively demon-
strated memory deﬁ  cits for inclusion in the study cohort, 
it becomes diﬃ     cult to demonstrate a relationship 
between amyloid burden and memory performance 
within the cohort. Additionally, as noted above, amyloid 
levels may approach asymptote by the MCI stage, and 
diﬀ  erences in brain amyloid burden beyond that point 
may have as much to do with modulating factors 
inﬂ  uencing the individual subject’s asymptotic level as 
they do with disease stage.
In cognitively healthy elderly subjects, Mintun and 
colleagues [52], Storandt and colleagues [62] and Jack 
and colleagues [54] reported no relationship between 
concurrent cognitive performance and 11C-PIB amyloid 
binding. Other studies have found mixed results. 
Mormimo and colleagues [63] reported a relationship 
between  11C-PIB amyloid binding and episodic memory 
for one population of normal elderly, but not for a second 
population. Rowe and colleagues [43] reported that 
subjects with high PIB amyloid binding had signiﬁ  cantly 
reduced memory scores relative to subjects with low 
amyloid binding, but the correlation between binding 
and memory was not signiﬁ   cant. In contrast, several 
studies [55,64,65] have now reported correlations 
between  11C-PIB amyloid binding and memory scores. 
Similarly, Rosenberg and colleagues [61] examined 
cognitive performance in the cohort of subjects described 
by Wong and colleagues [26] and found a signiﬁ  cant corre-
lation between ﬂ  orbetapir F 18 binding and ADAS-cog 
(Alzheimer’s Disease Assessment Scale Cognitive Sub-
scale) performance by normal elderly controls. Park and 
colleagues [66] have also recently reported a relation  ship 
between ﬂ   orbetapir PET amyloid binding and work  ing 
memory performance in cognitively normal aging subjects.
It is not surprising that the strength of correlation 
between PET result and cognitive performance, and/or 
the magnitude of the diﬀ  erence in cognitive performance 
between cognitively normal subjects with Aβ-positive 
and Aβ-negative PET scans, was modest and sometimes 
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magnitude of eﬀ  ect that can be obtained in cognitively 
normal subjects. First, the range of cognitive performance 
in cognitively normal subjects is constrained by the 
criteria used to separate cognitively impaired subjects 
from cognitively normal. Th   e earlier and more 
aggressively the diagnosis of impairment is made, the less 
potential for variance within the normal group as a 
function of amyloid level, as subjects with greater 
amyloid burden, and more advanced impairment, may be 
classiﬁ  ed as cognitively impaired. Second, the outcome 
may depend on the diﬃ   culty of the cognitive tests used. 
More diﬃ   cult tests are more likely to uncover deﬁ  cits 
that may otherwise go unnoticed [64]. Finally, the 
relationship between amyloid binding and cognitive 
performance can be modiﬁ  ed by the subject’s education/
cognitive reserve [64,65]. Subjects with high education/
high cognitive reserve appear to maintain cognitive 
function in the normal range for a longer period or in the 
face of greater PET amyloid binding than subjects with 
lower cognitive reserve.
Th  e Pike and colleagues [55] and the Rentz and 
colleagues [64] reports above both include scatterplots of 
cognitive performance as a function of amyloid binding 
(SUVR). Rather than a preferential distribution of abnor-
mally low memory scores in association with high amy-
loid binding, the scatterplots are notable for the relative 
absence of high memory scores in the high amyloid 
group. It is tempting to speculate that this kind of 
distribution is the result of the limiting factors discussed 
above. In the amyloid-positive cohort, subjects with low 
cognitive reserve cannot sustain performance and become 
classiﬁ  ed as MCI, whereas subjects with high cognitive 
reserve, who otherwise would have been above average 
memory performers, have deteriorated but are still per-
form  ing near the middle of the normal range. However, 
this kind of hypothesis can only be addressed by longi-
tudinal studies.
Th  e relationship between amyloid burden as assessed 
by PET imaging and longitudinal change in cognitive 
function in cognitively normal and MCI populations is 
currently under examination in multiple trials, including 
the US ADNI study [40] (11C-PIB, phase 1, and ﬂ  orbetapir 
F 18, phase 2), the Australian Imaging, Biomarkers and 
Lifestyle Initiative (AIBL) initiative [43] (11C-PIB) and 
several ongoing longitudinal trials of aging [62,67], as 
well as in several trials with 18F-labeled agents that are 
either still ongoing (ﬂ  utemetamol, NCT01028053; ﬂ  or-
beta  ben, NCT01138111; ClinicalTrials.gov) or recently 
completed (ﬂ  orbetapir) [59]. First results, now coming 
into the literature, strongly suggest a relationship 
between amyloid burden and AD progression.
Four published studies have examined the potential of 
11C-PIB PET amyloid imaging to predict progression 
from MCI to AD. Forsberg and colleagues [57] imaged 27 
MCI subjects and reported that 7 who subsequently 
converted to AD had higher PIB retention than non-
converting subjects. Okello and colleagues [56] studied 
31 MCI subjects, 17 (55%) of whom were considered 
amyloid-positive on an 11C-PIB PET scan. Of these 17 
subjects, 14 (82%) converted from MCI to AD in the 
follow-up period (up to 3 years). Only 1 of 14 (7%) 
amyloid-negative subjects converted in the same time 
period. A comparison of fast (<1 year) versus slower 
converters suggested that fast converters (within one year 
of scan; 8 of 17 amyloid-positive subjects) had higher 
11C-PIB PET cortical to cerebellar uptake ratios than the 
slower converters, despite a similar mean age. Notably, all 
fast converters for whom genotype was available carried 
an apolipoprotein E ε4 alleole, whereas only two of six 
slow converters with genotype information carried an 
apolipoprotein E ε4 alleole. Th   us, the ε4 alleole may have 
contributed to both the elevated amyloid burden 
(increased SUVR) and the more rapid conversion. Wolk 
and colleagues [68] similarly reported a higher rate of 
conversion in subjects classiﬁ  ed as amyloid-positive (5 of 
13, 38%) versus amyloid-negative (zero of 10) by 11C-PIB 
PET. Finally, Jack and colleagues [69] recently published 
the ﬁ  rst report of follow-up results from the ADNI study. 
Of 218 MCI subjects included in the analysis, 11C-PIB 
data were available for 53 subjects, and CSF Aβ levels, 
but not 11C-PIB, were available for 165. In order to increase 
power and to better draw conclusions regarding relation-
ships between amyloid burden and disease progression, 
CSF data from subjects who did not undergo 11C-PIB 
imaging were transformed to facilitate a combined 
quantitative analysis. Over the observation period, 81 of 
165 amyloid-positive versus 8 of 53 amyloid-negative MCI 
subjects progressed to AD. A Kaplin Meyer analysis 
estimated a signiﬁ  cantly increased hazard ratio (3.2) with a 
2-year estimated conversion rate of 50% in the amyloid-
positive versus 19% in the amyloid-negative subjects.
Only one study has reported progression of cognitively 
normal subjects to more advanced disease. Morris and 
colleagues [70] performed 11C-PIB scans in 159 cogni-
tively normal (Clinical Dementia Rating (CDR) 0) sub-
jects that were part of a longitudinal aging study and 
reported that the relative risk of conversion from CDR 0 
to AD (nine subjects) was increased almost ﬁ  ve-fold in 
the presence of a positive 11C-PIB amyloid scan. A lesser, 
non-signiﬁ   cant increase in risk was reported for 
conversion from CDR 0 to CDR 0.5 (n = 23).
Th  e primary weakness of studies using conversion/
stage change as an endpoint is that the rate of conversion, 
particularly from healthy to MCI or AD, may be low and 
variable across subjects and studies, depending on 
recruiting centers and entry criteria. Hence, three studies 
in cognitively normal aging elderly have looked instead at 
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tinuous measures, that is, change in objectively measured 
cognitive performance. Storandt and colleagues [62], 
working with essentially the same subject population as 
Morris and colleagues [70], found that concurrent 
cognitive performance was unrelated to 11C-PIB binding, 
but the estimated annual rate of cognitive deterioration, 
as evidenced by change in visuospatial and working 
memory performance composite scores, was signiﬁ  cantly 
greater in subjects with an amyloid-positive 11C-PIB PET 
scan than in subjects with an amyloid-negative 11C-PIB 
scan. High amyloid binding on 11C-PIB scans was also 
associated with reduced regional brain volume on MRI, 
further suggesting that even in cognitively normal 
subjects (CDR 0) amyloid accumulation is not benign. 
Villemagne and colleagues [71] imaged 34 elderly 
subjects that had been previously followed longitudinally 
for 6 to 10 years. On average, subjects with memory 
decline over the observation period had higher 11C-PIB 
retention; 7 of 11 subjects with elevated 11C-PIB retention 
showed memory decline, versus 4 of 23 subjects with 
normal 11C-PIB retention. Finally, Resnick and colleagues 
[67] obtained 11C-PIB PET images on 57 subjects who 
had been followed for an average of 10.8 years as part of 
the Baltimore Longitudinal Study of Aging and found a 
signiﬁ   cant correlation between 11C-PIB binding (DVR) 
and Mini Mental State Exam and verbal memory 
(California Verbal Learning Test).
One weakness of the Storandt and colleagues [62], 
Villemagne and colleagues [71] and Resnick and colleagues 
[67] studies is that they rely primarily on retrospective 
analysis of cognitive decline. Although several groups 
have now reported that change in 11C-PIB binding is 
relatively slow, particularly in amyloid-positive subjects 
[40,51], it is diﬃ   cult to judge from a retrospective analysis 
how early the 11C-PIB PET could have predicted subjects 
likely to show cognitive decline. Of course, these groups 
and others (for example, ADNI) are now following 
subjects prospectively from the point of imaging. One 
recent preliminary report [59] was consistent with the 
results above showing a relationship between ﬂ  orbetapir 
PET amyloid binding and prospectively measured cogni-
tive decline.
In summary, the data to date are limited, but taken 
together provide evidence that abnormal accumulation of 
Aβ as evidenced by PET amyloid imaging is associated 
with increased risk of both concurrent cognitive deﬁ  cits 
and subsequent progression of cognitive impairment, 
and thus may be pathological even in apparently cogni-
tively normal subjects.
Conclusion
Emerging consensus regarding diagnostic algorithms and 
criteria suggests that diagnosis of AD can be enhanced by 
use of biomarkers to increase certainty, and, in early 
stages, to identify the group of patients at risk for pro-
gression to AD. Th  e data reviewed above suggest that 
PET amyloid imaging may be well suited to both tasks. 
Amyloid binding on PET has been shown to be strongly 
correlated with brain Aβ burden at autopsy, and PET 
imaging identiﬁ  ed amyloid-positive subjects with a high 
sensitivity and speciﬁ  city in relationship to postmortem 
histopathological criteria for AD. Additionally, there is 
consistent evidence that PET imaging can identify 
subjects with elevated Aβ burden, even at early stages of 
disease, and preliminary evidence suggests that excess Aβ 
accumulation, as evidenced by PET imaging, has impli-
cations for both present and future cognitive performance.
Current theory suggests that Aβ accumulation may be 
a critical early step in a cascade of events, including 
phosphoryl tau and inﬂ  ammation-mediated  synaptic 
damage and neuronal loss, that leads to cognitive 
impairment in AD. Early identiﬁ  cation of subjects with 
Aβ accumulation may be critical to the development of 
potential disease-modifying therapies because amyloid 
targeted therapies may not be eﬀ  ective once later stages 
of the cascade have begun.
Th   ere is an opportunity to identify patients earlier than 
occurs in current clinical practice. Typical patients in 
clinical trials, who are generally well educated and well 
integrated into the medical system, report delays of 
approximately 2 years between symptom onset and 
diagnosis. Delays may be even greater in a community 
setting where physicians are known to overlook diag-
noses in a substantial proportion of patients. However, 
improved diagnostic aids, such as amyloid-targeted PET 
scans, alone may not be suﬃ     cient to overcome this 
problem. Diagnostic delays may be partly a matter of 
patient education (recognition and acceptance of AD 
symptoms, readiness to seek treatment) and physician 
practice. In particular, some physicians may be unwilling 
to commit to diagnosis in the absence of viable treat-
ments. On the other hand, tools that provide evidence of 
the underlying pathology might improve physician’s 
conﬁ  dence, and lead to an earlier diagnosis, by reducing 
the need for longitudinal follow-up and progression to a 
more advanced stage of symptoms. Equally important, 
the evidence indicates that PET amyloid scans can 
identify patients with early cognitive impairments who 
do not have pathological levels of brain Aβ at autopsy. 
Since Aβ pathology is required for a diagnosis of AD, the 
early demonstration of the absence of Aβ may lead 
instead to further evaluation of potentially treatable 
causes of impairment (for example, depression) in these 
patients.
When, and in what population of patients, should 
amyloid PET imaging be used? It is easy enough to 
identify and rule out the extremes. On the one extreme, a 
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beyond the point where a scan would inﬂ  uence medical 
management would likely derive little beneﬁ  t from a PET 
scan. On the other extreme the evidence to date is not 
suﬃ   cient to support routine use in screening cognitively 
normal subjects, even in the presence of risk factors. 
Although the results discussed above (for example, 
[55,61]) suggest that subjects who are amyloid-positive 
on PET scan may perform worse on cognitive tests, the 
results have not been entirely consistent across trials, and 
the eﬀ  ects are subtle and of uncertain clinical relevance. 
Most important, too few amyloid-positive subjects have 
been identiﬁ   ed and followed longitudinally to give 
guidance to the patient regarding likelihood and time 
course of future cognitive deterioration. Current esti-
mates of 10 years or more between the ﬁ   rst signs of 
excess Aβ accumulation and onset of dementia suggest 
that many amyloid-positive elderly patients might pass 
on before experiencing signiﬁ  cant cognitive decline.
In between these extremes lie a large number of 
patients that could potentially beneﬁ  t from PET amyloid 
scans. With three 18F-labeled amyloid targeted ligands 
having entered or already completed phase III trials, it is 
likely that amyloid PET scans will be broadly available 
within the next few years. Additional studies and con-
sensus evaluations are needed to determine the best use 
for these agents. Despite the positive results des  cribed 
above, it is clear that an amyloid PET scan is not suﬃ   cient 
to confer a diagnosis of AD. Aβ can be present in 
association with other disease conditions, including DLB, 
Parkinson’s disease and cerebrovascular disease. It 
remains unclear whether this reﬂ  ects the coincidence of 
two or more disease entities (for example, AD indepen-
dently in addition to DLB) or whether Aβ (and tau) 
pathology can be found independently in multiple disease 
entities.
In either case, the advent of PET amyloid imaging tech-
niques does not obviate the need for clinical/cognitive 
evaluation. Moreover, the information obtained from 
amyloid PET imaging may be enhanced by additional 
biomarker studies, including, for example, functional 
imaging [72], or molecular imaging aimed at dopamine 
systems [73-75]. Additional studies are required to 
identify which patients most beneﬁ  t from PET amyloid 
imaging and which additional diagnostic assessments are 
most useful in developing a practice parameter to 
optimize the potential for early evaluation of cognitive 
impairment.
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